Patricia Piatti

  • Why so many companies are betting on PROTACs as a superior therapeutic modality

    Why so many companies are betting on PROTACs as a superior therapeutic modality

    With PROTACs currently in the clinical and preclinical stages, they are making exciting progress towards successfully treating patients who have been waiting for effective therapies for certain...

    Read
  • Protein degraders show promising results in drug development pipelines. See progress candidates have made.

    Protein degraders show promising results in drug development pipelines. See progress candidates have made.

    There has been considerable and promising development in the field of targeted protein degradation (TPD) since the seminal discovery of PROTACs in 2001.1 The appeal of degraders like PROTACs lies...

    Read
  • Is your screening campaign stuck? 3 signs that it’s time to look for an alternative biophysical technology

    Is your screening campaign stuck? 3 signs that it’s time to look for an alternative biophysical technology

    Most labs dedicated to drug discovery — in big pharma, biopharma, or CROs — make it a priority to have an adequate lineup of instruments for their screening campaigns. They decide on what...

    Read
  • Follow these 7 tips when pipetting small volumes to get consistent assay results

    Follow these 7 tips when pipetting small volumes to get consistent assay results

    If you’ve ever had to pipette really small volumes, such as what is required in 384-well plates, you’re definitely familiar with the frustrations that come along with it. The concentration alone...

    Read
  • loading
    Loading more...